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Background: The objectives of this study were to explore the relationship between olfactory impairment, cognitive
measures, and brain structure volumes in healthy elderly individuals, compared to patients with amnestic mild
cognitive impairment (aMCI) or early Alzheimer’s disease (AD). The primary aim was to elucidate possible differences in
cognitive scores and brain structure volumes between aMCI/AD patients with relatively intact odor identification (OI)
ability and those with reduced ability.
Methods: Twelve patients with aMCI, six with early AD, and 30 control subjects were included. OI abilities were
assessed with the Brief Smell Identification Test (B-SIT) and Sniffin Sticks Identification Test (SSIT). Neuropsychological
tests of executive functions and memory were performed. Brain structural volumes were obtained from T1 weighted
3D MRI at 3 Tesla. Statistical comparisons between the patients with aMCI and AD indicated no significant differences
in performance on most tests. Since the groups were small and AD patients were in an early phase of disease, all
patients were subsequently considered together as a single group for studying OI. Patients were subdivided into
relatively intact (scores >50%) and reduced OI (≤ 50% score) on the olfactory tests.
Results: The aMCI/AD group with reduced OI ability, as measured by both B-SIT and SSIT, had significantly smaller
hippocampal volume as compared to the patient group with OI scores > 50%. There was a significant association
between OI scores and hippocampal volume in the patient (not the control) group. Similar changes with tests of
executive function and memory were not found. Low OI scores on B-SIT were associated with conversion from aMCI
to AD in patients. The reduced OI patient group was significantly faster on Rey complex
figure copying than the fairly intact OI group.
Conclusion: The results from this pilot study suggest that the reduction in the size of hippocampus in connection
with early AD is associated more with loss of OI ability rather than loss of memory, thus demonstrating that impaired
OI is an early marker of medial temporal lobe degeneration.
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Tests of odor identification (OI) can discriminate neuro-
degenerative diseases, such as Alzheimer’s disease (AD)
from normal aging, with high sensitivity and specificity
[1]. The first observed olfactory deficit in patients with AD
is not the ability to detect various odors, but to identify
them correctly [2,3].
Olfactory deficits have also frequently been reported
in mild cognitive impairment (MCI) [4,5], and there
seem to be no significant differences between non-
amnestic and amnestic MCI (aMCI) regarding OI per-
formance [6]. Interestingly, studies using the Brief Smell
Identification Test (B-SIT) show that both probable
AD patients [7] and MCI subtypes score throughout
the range of the test [6], thereby indicating that some
probable AD and MCI patients have a relatively intact
OI ability. OI ability can therefore not be used to dis-
tinguish patients with MCI from those with AD [8].
The reason why some patients retain OI ability longer
than others is unknown, and we wished to investigate
this further in the present study.
Pathological changes in different areas of the olfac-
tory system have been suggested to cause the deficits
of OI function in patients with AD, as well as other
forms of dementia [9]. The OI deficit has been shown
to correlate with the number of tangles in the entor-
hinal cortex and hippocampus in AD pathology [10].
Neuroimaging studies support a particular role for the
medial temporal lobe in OI in healthy controls, and in
normal aging the activity during OI decreases in these
areas with age [11-16]. Cross-sectional and longitu-
dinal volumetric studies have demonstrated a strong
correlation between volume of the hippocampus and
OI ability in AD [17-19]. Other non-CNS factors pos-
sibly affecting olfaction in AD include deposits of tau
protein and beta-amyloid in the olfactory epithelium,
and a reduced number of mitral cells and axonal loss
in the olfactory tract [20]. OI performance has been
shown to be associated with cognitive speed, verbal
fluency, and memory in healthy controls and MCI/AD
patients [5,21-23].
There is currently little information regarding fac-
tors that differentiate patients with comparatively
intact compared to impaired OI function in early AD,
though OI has been found to predict conversion of
MCI to AD [24,25]. The main goal of this study was
therefore to explore the relationship between the
integrity of OI function, cognitive measures, and brain
structure volume in healthy elderly individuals,
compared to patients with aMCI or early AD. We also
wished to examine whether differences in cognitive
measures and brain structure volumes could be
detected when patients were divided according to their
OI ability.Methods
Subjects and diagnostic procedure
In total 18 consecutive patients (eight males) recruited
from the Memory Clinic, Department of Geriatrics, St.
Olav Hospital (University Hospital of Trondheim) who
agreed to participate, were included in this study. Patients
were examined according to a standardized protocol for
the Memory Clinic, following recommended international
standards [26]. The diagnostic work-up with medical
history was obtained from both patients and their care-
givers. A clinical examination, including neuropsychology,
cardiovascular status, neurological examination, and cere-
bral MRI at 3 T was performed which included the
T1-weighted 3D volume from the Alzheimer Disease
Neuroimaging (ADNI) MRI protocol. AD was diagnosed
by an experienced geriatrician and assessed according to
the criteria of the International Classification of Diseases
(ICD-10) and the National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association (NINCDS-
ADRDA) [27]. Patients fulfilling the accepted US National
Institute on Aging-Alzheimer’s Association (NIA-AA)
diagnostic criteria for aMCI were also included [28].
Of the 18 patients included, 12 were diagnosed with
aMCI at baseline and six with early AD.
An additional 30 controls (16 males) were recruited by
invitation through senior citizen centers, posters in the
Trondheim area, alumni links, and personal networks.
Patients and controls were excluded if they were not
MRI-compatible, affected by some other serious somatic
or psychiatric illness with an impact on activities of daily
living, had nasal-sinus pathology, previous head trauma
with loss of consciousness, brain infection, or had a viral
infection at the time of the investigation.
All subsequent testing of participants was carried out
at baseline. Relevant clinical data were gathered from
patient records. Samples were taken for genomic DNA
extraction from peripheral EDTA-blood and screened
for APOE genotypes. Education level and smoking habits
were recorded for each participant. In addition anterior
rhinoscopy was performed in both patients and controls
to check whether they had nasal polyps, tumor, or a
pathological obstruction in the anterior nasal cavity. All
individuals were checked for a history of olfactory, nasal
and/or respiratory problems. A high resolution coronal
T2-weighted scan of the sinuses and nasal cavity at 3 T
(Siemens Trio scanner with a 12-channel Head Matrix
Coil, Siemens AG, Erlangen, Germany) was obtained to
identify any abnormalities in these structures not revealed
by anterior rhinoscopy. To the best of our knowledge,
no medications taken by patients or controls would
have affected their olfactory performance.
All patients were assessed clinically 6–18 months (mean
9.9 months) later; 13 patients were then diagnosed with
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follow-up as there was no ethical board approval for this.
Since the writing of this manuscript, an additional patient
with aMCI is known to have developed AD.
This study conformed to the Declaration of Helsinki.
All participants received written information about the
project and gave written consent. The study was approved
by the Regional Committee of Medical Research Ethics for
central Norway, and the Norwegian Data Inspectorate.
Neuropsychological tests
The neuropsychological test battery included the Mini
Mental Status Examination (MMSE), Trail Making Test
A and B (TMT-A and TMT-B) [29], the Ten-Word Test
(TWT) from the Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD), the Rey-Osterrieth Complex
Figure Test (RCFT) [30], and a non-standardized Stereo-
gnosis Test in which the participants were presented with
twelve different common objects (e.g. key, doll, pencil, clock
and coin) placed in their hand without any visual cues
(blindfolded).
Psychophysical measurements
Olfactory measurements included The Brief Smell Iden-
tification Test (B-SIT, Sensonics Inc., Haddon Heights,
USA), the Sniffin Sticks Identification Test (SSIT, Burghart
Messetechnik GmbH, Wedel, Germany), and the Sniffin
Sticks Discrimination Test (SSDT, Burghart Messetechnik
GmbH, Wedel, Germany). SSDT was performed with only
16 of the patients. In B-SIT, a 12-item, four-choice,
scratch-and-sniff identification test, the odorants are
released from strips scratched with a special pencil. In
SSIT the odor is released when removing the pen cap,
with the pen positioned approximately two cm in front
of both nostrils. Subjects were allowed to sniff SSIT-pens
only once for three to four seconds. In both tests, the
alternatives for the odorants were given orally twice by
the experimenter, once before smelling the odor and
again afterwards. The main difference in administration
of the two tests was that in SSIT the test subjects could
read the alternatives as well as hear them, whereas the
alternatives in the B-SIT were written in English and
not translated. The SSDT consists of 16 triplets, where
two pens have the same smell, while one of the three
pens contains a different odor. Participants were asked
to identify the pen that had the different odor and were
blindfolded because the pens were color-coded. Partici-
pants must choose one of the three pens of the triplet
even when they do not perceive or recognize a different
odor. In each olfactory test, correctly-identified odors
received one point, giving a possible score range of 0–12
points for B-SIT, 0–16 for SSIT, and 0–16 for SSDT.
Subsequent comparison between the patients with aMCI
and AD at baseline indicated no significant differencesin performance on most tests, the only exceptions being
weak significant differences with RCFT copying (p = 0.044),
and TMT-A (p = 0.047). Taken together, as the groups
were small and AD patients were in an early phase of
disease (as assessed by MMSE: minimum score = 20,
mean score = 24.8), both aMCI and AD patients were
subsequently considered together as a single patient
group for studying OI.
For further analysis of their OI abilities, this combined
group of patients was divided according to performance
on B-SIT and SSIT. For B-SIT the cut-off point was set to
6 such that patients scoring ≤ 6 (≤50%) were considered
to have reduced OI ability (n = 6), and those scoring ≥7
(>50% score) were considered to have intact, or com-
paratively intact OI ability (n = 12). For SSIT, patients
scoring ≤ 8 (≤50% score) were considered to have reduced
OI ability, while those scoring ≥9 items correctly (>50%
score) were considered to have intact, or comparatively
intact OI ability.
The patient group was also split according to perform-
ance on delayed recall of the TWT (http://www.dia-online.
no/tools/cerad%2010-ord%20fullstendig.doc), to indicate
whether the results seen with the olfactory tests could
be reproduced with a verbal memory test. Subgrouping
patients below age 80 according to those scoring four
or more (considered to indicate intact, or comparatively
intact memory) or less than four (considered to indicate
reduced memory), and at age 80 or over scoring 3 or
more (intact, or comparatively intact memory) or less
than three (reduced memory), resulted in a total group
with at least comparatively intact memory of n = 6, and
a group with reduced memory of n = 10 (n = 2 missing).
Brain structural MRI volume
From all participants one T1-weighted 3D scan was
obtained in the sagittal plane with repetition time
(TR) = 2300 ms, echo time (TE) = 2.94 ms, field of
view 256 mm, flip angle = 8, slice thickness = 1.00 mm,
voxel size = 1.0*1.0*1.0 mm, slices per slab = 192, and
base resolution = 256.
The T1 weighted volumes were analyzed using Neuro-
Quant (CorTechs Labs Inc., CA, USA) which performs
automatic anatomical segmentation and volumetric meas-
urement of brain structures (http://www.cortechs.net/
index.php). Neuroquant is a fully automated segmentation
FDA-cleared tool for clinical evaluation of hippocampal
atrophy in mild cognitive impairment and Alzheimer’s
disease [31-33]. The output from Neuroquant also
includes other brain regions such as total hemispheric
white matter, total cortical grey matter, lateral, third,
fourth, and inferior lateral ventricle, cerebellum, amygdala,
caudate, putamen, pallidum, thalamus and brainstem
volumes. In this study brain regions related to olfactory
processing were included in further analysis; total
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hippocampus, amygdala, and the total ventricular space.
The volume of each structure was calculated as a percent-
age of the overall intracranial volume. The volume of
structures such as the entorhinal cortex could not be
determined by Neuroquant and is therefore not part of
this study, although this region is considered central for
both AD and OI [11,34]. In this study volumes relative
to ICV (% ICV) are used. The ICV-corrected volumes
of the segmented structures from the left and right
hemispheres were combined.
Statistical analysis
Statistics were calculated using SPSS version 17 (SPSS Inc.).
The B-SIT and SSIT tests were not normally distributed
because they contain only unsigned integers. However, a
Kolmogorov-Smirnov test on the whole material (patients
and controls) indicated that the distribution of B-SIT
and SSIT scores was not significantly different from
normal (p > 0.1).
Psychophysical measurements, neuropsychological tests
and volumetric measurements are reported as the mean ±
SD. An independent samples t-testa and ANCOVA for
correction of age, were used to test for significant dif-
ferences between the patient and the control groups.
Correlations between SSIT and B-SIT scores were
assessed separately for the patient and control group.
The chi-square test was used to compare occurrence
of the APOEε4 genotype, gender, smoking habits and edu-
cation level in patients and controls. P-values less than
0.05 were considered significant.
Relationships between brain volumes or neuropsycho-
logical test results and the OI test scores subgrouped
according to B-SIT or SSIT scores as “ > 50%” or “ ≤ 50%”
were examined using Levene’s test for equality of
variances with an independent t-test, plus a Bonferroni
correction (3 comparisons), significance level adjusted to
p < 0.017. Cohen’s d was used to measure the effect size of
group differences between the “ > 50%” and “ ≤ 50%” OI
groups. Group differences in brain volumes between the
different groups were also assessed and corrected for age
or TWT (delayed recall scores) in an ANCOVA, as appro-
priate. The kappa test was used to compare B-SIT and
SSIT for discriminating patients from controls. Sensitivity
and specificity were also calculated for B-SIT and SSIT.
Linear regression analysis was carried out between hippo-
campal volume and the olfactory as well as the memory
tests in the control and the patient group separately.
Results
In this material, the combined group of patients with
aMCI or AD was found to be significantly older than
the control group, and had a much higher incidence of
the APOEε4 genotype (p = 0.001), but no significantdifferences were found in education level or smoking
habits between the groups (Table 1). When patients were
subdivided according to their performance on B-SIT
(≥7 or ≤ 6 correct items), no significant differences were
found in the demographic data, or any cognitive test,
between patients in the two subgroups. When patients
were divided according to their performance on SSIT
(≥9 or ≤ 8 correct items), a significant difference in gender
was found (Table 1). There was no significant difference
in the distribution of the APOEε4 allele between these
subgroups.
Performance on olfactory identification tests
Patients performed significantly worse than healthy con-
trols on the two OI tests, but not on the odor discrimin-
ation test SSDT (Table 1). This result was unaltered when
correcting for age. Figure 1 shows a positive correlation
between B-SIT and SSIT in both the control (r = 0.606,
p < 0.0005), and patient groups (r = 0.514, p = 0.042).
Although all control individuals were considered cogni-
tively intact at inclusion, it can be seen from the figure
that two individuals, both men, had very low scores on
both olfactory tests. However, they had MMSE scores
of 27 and 29 respectively, and scored in the upper end of
the TWT and RCFT. Nevertheless, B-SIT distinguished
patients from controls when using a cut-off of ≥7/≤6
correct items [26], with a value of κ = 0.63, sensitivity
0.86 and specificity 0.82. Corresponding values for SSIT
using a cut-off of ≥ 9/≤8 correct items were κ = 0.35,
sensitivity 0.75 and specificity 0.74.
When patients were subdivided according to scores on
B-SIT or SSIT, the number of patients scoring either > 50%,
or ≤ 50% was not identical; more patients were considered
to have comparatively intact OI by SSIT than B-SIT. How-
ever, all those considered to have comparatively intact OI
by B-SIT were also considered so by the division according
to SSIT. The five patients with aMCI who had not pro-
gressed to AD by 18 months were not concentrated into
the > 50% group, but were divided 3 > 50% score: 2 ≤ 50%
score with both tests. Neither OI score cut-off significantly
distinguished results for SSDT (Table 1).
Performance on cognitive tests
Patients performed significantly worse than healthy
controls on all cognitive tests, with the exception of
TMT-A (Table 1). The results were similar when cor-
recting for age. The only difference found between the
OI subgroups concerning the cognitive tests was sig-
nificantly faster RCFT figure copying in the impaired
OI group according to the division by SSIT (Table 1).
There were many significant correlations between the
cognitive and OI tests, but this aspect is well known
[2,4,17,35], and these results are not considered further in
the present study.

















Gender (female/male%) 46.7/53.3 55.6/44.4 66.7/33.3 50.0/50.0 70.0/30.0 16.7/83.3+
Age (years) 67.4 ± 7.6 74.6 ± 6.3** 76.0 ± 7.8 73.8 ± 5.7 76.5 ± 1.3 72.3 ± 5.1
Education (years) 17.1 ± 3.5 15.3 ± 2.5 15.3 ± 1.3 15.3 ± 3.0 14.8 ± 1.9 16.8 ± 3.4
Daily smokers (%) 3.3 5.6 0 8.3 0 0
APOE Ɛ4 genotype (% carriers 1–2 alleles) 20.8 73.3** 75.0 72.7 62.5 83.3
Cognitive tests
MMSE (max. score 30) 28.7 ± 1.2 25.5 ± 2.5** 26.0 ± 1.7 25.3 ± 2.8 26.0 ± 1.6 25.7 ± 3.0
Ten-word test, total recall
(max. score 30)
22.7 ± 3.6 12.5 ± 3.8** 13.2 ± 3.7 12.1 ± 3.9 12.1 ± 3.6 14.0 ± 4.2
Ten-words tests, delayed
recall (max. 10)
8.1 ± 1.9 2.2 ± 1.7** 3.2 ± 1.8 1.6 ± 1.4 2.5 ± 1.9 1.8 ± 1.5
RCFT, figure copying 30.9 ± 3.0 26.0 ± 5.1** 24.6 ± 4.6 26.8 ± 5.4 23.9 ± 4.3 29.8 ± 4.4+
RCFT, immediate recall 17.9 ± 5.6 6.3 ± 4.4** 6.2 ± 6.1 6.4 ± 3.5 6.0 ± 4.6 6.8 ± 4.6
RCFT, delayed recall 17.7 ± 5.3 6.9 ± 4.2** 7.2 ± 6.8 6.7 ± 2.0 7.5 ± 4.8 5.9 ± 3.5
Stereognosis (max. score 12) 11.5 ± 0.8 10.2 ± 2.2** 10.2 ± 1.6 10.2 ± 2.6 10.6 ± 1.4 9.5 ± 3.2
Trail Making A (sec) 52.6 ± 20.1 64.7 ± 21.8 61.2 ± 15.9 64.2 ± 24.5 66.0 ± 21.4 66.7 ± 25.7
Trail Making-B (sec) 104.1 ± 37.5 134.0 ± 51.8* 141.0 ± 58.9 127.0 ± 48.3 148.3 ± 47.7 126.3 ± 56.2
Phychophysical mesurements
B-SIT (12 items) 9.6 ± 2.0 6.6 ± 2.6** 9.8 ± 1.6 5.0 ± 0.7## 7.4 ± 2.6 5.7 ± 2.7
SSIT (16 items) 12.7 ± 2.4 9.4 ± 3.0** 11.3 ± 3.1 8.2 ± 2.3# 11.1 ± 2.1 6.5 ± 1.8+
SSDT (16 items) 9.2 ± 3.3 7.5 ± 3.0 7.8 ± 3.4 7.3 ± 3.0 7.4 ± 2.9 7.6 ± 3.5
Where appropriate, the mean ± SD is shown.
Significant differences using Student’s t-test for total group of patients compared to controls: *p < 0.05, **p < 0.005.
Significant differences using Student’s t-test for scoring >50% or ≤50% on B-SIT: #p < 0.05, ##p < 0.005.
Significant differences using Student’s t-test for scoring >50% or ≤50% on SSIT: +p < 0.05.
B-SIT; Brief Smell Identification Test, SSIT; Sniffin Sticks Identification Test, SSDT; Sniffin Sticks Discrimination Test, MMSE; Mini-Mental State Examination,
RCFT; Rey-Osterrieth Complex Figure Test.
Patients have also been divided according to their odor identification (OI) ability.
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The B-SIT score did not differentiate patients with aMCI
from those with AD at baseline (p > 0.4), but prospectively
differentiated those patients persisting with aMCI from
those who had progressed to AD 6–18 months later
(mean 9.9 months, t-test; p = 0.037). SSIT scores did not
differentiate patients converting to AD. The respective
percentages of patients judged to have reduced OI ability
by B-SIT (≤50% score) for patients with aMCI who did
not convert to AD during the follow-up period, patients
with aMCI who converted to AD, and those with AD from
baseline, were respectively 40%, 71% and 83%. Similar
figures for SSIT were respectively 25%, 29% and 60%.
Comparing patients with aMCI and AD at baseline did
not show any significant differences in B-SIT scores,
SSIT scores, or structural brain volumes.Structural MRI volumes in patients compared to controls,
and to cognitive tests
Volumetric MRI measurement of brain structures dem-
onstrated significantly smaller cortical gray matter in
patients compared to controls, but no overall significant
reduction in the volume of the hemispheric white matter
between patients and controls even after correction for age.
The most marked differences were found in hippocampus
and amygdala, which were both significantly smaller
compared to controls. The overall ventricular volume was
significantly increased in patients compared to controls
(Table 2). Regression analysis demonstrated that a reduc-
tion in the OI ability as measured by both B-SIT and SSIT
was associated with smaller hippocampal volume in
patients but not controls (Table 3). However, MMSE,
TWT and RCFT (immediate and delayed recall) scores
Figure 1 Significant positive correlation between the Brief Smell Identification Test (B-SIT), or Sniffin Sticks Identification Test (SSIT) in
both the control group (r = 0.606, p < 0.0005), and patient group (r = 0.514, p = 0.042).
Table 3 Regression coefficients (linear regression
analysis) between hippocampal volume in patients and
controls, and odor identification and memory tests
Tests Hippocampal volume
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In the control group significant associations between
hippocampal volume and MMSE (p = 0.014) and delayed
recall of the Ten Word Test (p = 0.043) scores were found
(Table 3).
Relationship between structural MRI volume and odor
identification
Brain structure volume in patients were also compared
according to the subdivisions of > 50% and ≤ 50% score
on B-SIT or SSIT, and are shown in Table 4. The volume
of hippocampus was significantly reduced in patients
scoring ≤ 50% compared to those scoring > 50% regardless
of whether OI was subdivided according to cut-offs for
B-SIT or SSIT. Additionally, poor performance on bothTable 2 Volumetric measurements for several brain





Hemispheric white matter 30.34 ± 1.90 29.37 ± 2.21
Cortical grey matter 29.46 ± 1.65 27.67 ± 1.84*
Hippocampus 0.49 ± 0.05 0.41 ± 0.04**
Amygdala 0.23 ± 0.02 0.20 ± 0.03**
Thalamus 1.20 ± 0.07 1.09 ± 0.07
Total ventricular volume 0.47 ± 0.15 0.74 ± 0.23**
Independent sample t-test (two-tailed): *p < 0.05 and **p < 0.005.
For bilateral structures volumes in the two hemispheres were combined,
and all values are given as a percentage of total intracranial volume.B-SIT and SSIT was associated with a significantly smaller
hippocampal volume in the group defined as having ≤ 50%
scores compared to that defined as having > 50% scores
with a very large effect size (Cohen’s d = 1.3 for groups
subdivided by B-SIT, and Cohen’s d = 1.9 for groups subdi-
vided by SSIT). These differences remained significant
after correction for performance on delayed recall of the
TWT (B-SIT p = 0.011; SSIT p = 0.011). When the patient
group was split according to performance on the TWT




B-SIT 0.58 (0.012)* 0.10 (0.60)
SSIT 0.71 (0.002)* 0.22 (0.26)
MMSE 0.36 (0.18) 0.46 (0.014)*
Ten-word test, total recall 0.03 (0.91) 0.20 (0.30)
Ten-word test, delayed recall 0.21 (0.43) 0.38 (0.043)*
RCFT, figure copying −0.53 (0.06) 0.03 (0.86)
RCFT, immediate recall 0.002 (0.99) 0.04 (0.85)
RCFT, delayed recall 0.15 (0.62) 0.12 (0.60)
Linear regression analysis: *p < 0.05B-SIT; Brief Smell Identification Test, SSIT;
Sniffin Sticks Identification Test, MMSE; Mini-Mental State Examination, RCFT;
Rey-Osterrieth Complex Figure Test.
Table 4 MRI volume of brain areas in patients with amnestic mild cognitive impairment or early Alzheimer’s disease,
where patients have been subgrouped according to odor identification (OI) ability
B-SIT SSIT
Brain areas Patients Patients
>50% score n = 6
mean ± SD
≤50% score n = 12
mean ± SD
>50% score n = 10
mean ± SD
≤50% score n = 6
mean ± SD
Hemispheric white matter 28.72 ± 2.49 29.40 ± 1.94 28.75 ± 1.96 30.49 ± 2.06
Cortical grey matter 27.77 ± 1.77 28.06 ± 1.25 28.15 ± 1.25 26.49 ± 2.46
Hippocampus 0.45 ± 0.02 0.41 ± 0.04a 0.44 ± 0.02 0.38 ± 0.04a
Amygdala 0.22 ± 0.04 0.18 ± 0.02 0.21 ± 0.03 0.17 ± 0.03a
Thalamus 1.10 ± 0.07 1.10 ± 0.08 1.13 ± 0.07 1.20 ± 0.56
Total venticular volume 0.86 ± 0.16 0.65 ± 0.22 0.81 ± 0.24 0.72 ± 0.18
aSignificant difference between patients subgrouped as having > 50% or ≤ 50% score according to either the Brief Smell Identification Test (B-SIT), or Sniffin Sticks
Identification Test (SSIT), p < 0.017.
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compared to those scoring ≤ 50% on TWT.
Volumes of both cortical gray matter and amygdala
were significantly smaller in the patient subgroup scor-
ing ≤ 50%, again according to the cut-off for both B-SIT
and SSIT, compared to controls (Table 2). However, amyg-
dala volume was significantly less in the patient subgroup
scoring ≤ 50% compared to those scoring > 50% only ac-
cording to the cut-off for SSIT, again with a large effect size
(Cohen’s d = 1.3 for groups subdivided by SSIT). A smaller
amygdale size was also observed with B-SIT, but did not
reach the level of significance.
Discussion
The number of patients included in the present study was
low, with a high mean age. It was both difficult to recruit
patients from the geriatric memory clinic, and difficult
for those volunteering to fulfill all inclusion criteria and
perform all the tests. However, the most important result
in the present study is that impaired OI performance, as
measured by two separate olfactory tests, B-SIT and SSIT,
is related to differences in the volume of several brain
structures, most particularly the hippocampus. Notably,
this difference in volumes was found within the patient
group when subdivided according to performance on the
two OI tests (divided according to those with compara-
tively intact OI (>50% score) and those with reduced OI
(≤50% score on B-SIT and SSIT), as well as between a
group consisting of patients with aMCI or AD, and
healthy control individuals. Validated cut-offs for olfactory
tests have been established [8,24], but in the present small
study the main aim was to compare patients on the
basis of changes in the volume of brain areas with their
OI abilities, as well as changes in memory. We also
wished to see if the results were similar in two separate
OI tests, which required establishing a cut-off for each
that should bear a relationship to each other, where
each test would reflect a similar change in OI ability(individuals with comparatively intact OI performance,
as opposed those with little or no OI ability). Although
this division is arbitrary, those with 50% scores or less
will probably have a compromised OI, and it is unlikely
that patients will achieve over 50% on such tests purely
by chance (achieving 7 correct answers on B-SIT by chance
is p = 0.011, and achieving 9 correct answers on SSIT by
chance is p = 0.006). That the patients in the subgroup
scoring ≤ 50% had smaller hippocampal volume than the
subgroup scoring >50% on the olfactory tests, suggests that
the former subgroup had greater atrophy in this brain
area. Despite this being a study with small groups, the
effect size was calculated to be from high to very high. It
is of course possible that some of the controls, such as the
two with the very low OI scores, could in time develop
AD or another neurodegenerative condition. However,
pathological tendencies in the control group would
probably have reduced the difference with patient group
rather than accentuating it.
The cognitive tests (with the exception of TMT-A),
odor tests (except SSDT), and volumetric MRI (with the
exception of cortical white matter and thalamus), were
all capable of clearly distinguishing the patient group
from healthy elderly controls, as expected [2,6,17]. These
results from B-SIT and SSIT support previous studies
that the group average of OI scores is lower in patients
with AD and MCI compared to healthy controls [1,6,17].
Moreover, B-SIT and SSIT correlated well with each
other in both groups.
Within the patient group, neuropsychological tests
applied did not distinguish between the OI subgroups.
The cognitive tests in general did not tend to show an
association with hippocampal volume, though MMSE
and the delayed recall part of the TWT were found to
correlate significantly among controls. MMSE scores for
controls were all ranged from the maximum 30 points to
a minimum of 27, whereas patient scores ranged from 28
to a minimum of 20 points. Apart from the small size of
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tests, even among cognitively intact elderly individuals. In
addition to age, these may include aspects such as the
level of education and other psychological conditions.
Such aspects may contribute to a spread of memory ability
across a control group, but result in a different association
in connection with a patient group with a progressive
dementia, in addition to other environmental and age-
related aspects.
It could be argued that as the patient group was older
than the controls, differences in cognition could be
accentuated, since both neuropsychological and odor
tests have been shown to correlate with age [36,37].
However, the statistical differences between the control
and patient groups remained significant after correction
for age. Furthermore, there was no significant difference
in age between the patient subgroups. Thus, parameters
other than age most likely contributed to the differences
in OI test scores between the subgroups. It seems
unlikely that smoking could have affected the results as
only one smoker was present in the control group, and
one in the patient group. This patient did show reduced
OI ability on B-SIT (and did not carry out SSIT), but
was a patient with a diagnosis of AD at baseline, and as
a group, these patients had low B-SIT scores.
In the patient group, the negative beta value found for
the figure-copying part of the RCFT and hippocampal
volume, though only a strong trend, suggests that patients
with smaller hippocampal volume copy the figure faster
than those with a larger volume. Copying of course does
not require memory. It is interesting that this part of the
RCFT was performed better by the patient group scoring
≤50% on SSIT. A larger test group would be needed to
confirm whether this result is correct or a chance finding.
Apart from these aspects, the cognitive tests in general
did not tend to show an association with hippocampal
volume. Although it is important to treat results from
small studies with care, the most consistent results here
were obtained with B-SIT and SSIT.
The results showed that the two OI tests subdivided
the patient group differently, the cut-off for SSIT defining
only six patients with scores of ≤ 50%, whereas 12 patients
scored 50% or less with B-SIT. A possibility for this may
well have been because the tests themselves involved
slightly different approaches to measuring olfaction: with
B-SIT, information concerning the odor alternatives was
only given orally, whereas with SSIT, alternatives were
available both orally and visually (they could be read). The
additional visual cue in SSIT was perhaps enough to
improve the performance of certain patients on this
test. Of the six patients who scored inconsistently on
the two tests, three were only borderline differences.
Indeed, although more patients were considered to have
only slight loss or normal OI according to the cut-off forSSIT, all those considered so by B-SIT were among them.
This may also explain why both tests tended to show
similarities in the volumetric data despite the difference
in OI group-assignment.
There was no clear connection found between the
clinical diagnosis, and the olfactory and volumetric data.
It might have been expected that patients maintaining a
diagnosis of aMCI throughout the study would have
better OI according to the olfactory tests, while those
with AD, as well as those progressing to AD, would
more often display reduced OI. Some evidence for such
a relationship between B-SIT and disease progression was
evident, as shown by the prospective difference between
mean B-SIT scores between patients with persisting
aMCI compared to those with AD at follow-up, and the
increases in percentage of patients showing a reduction
in OI ability between those maintaining aMCI over the
follow-up period, those converting to AD, and those with
AD at baseline. However, our results overall further
support observations that loss of OI ability tends to
occur early in AD, although this is not absolute [1].
That so many patients converted from aMCI to AD in
a short space of time in this study perhaps helps explain
why there were so few statistical differences between
patients with aMCI compared to AD on the cognitive
tests. A higher conversion rate should be expected when
only patients with aMCI are included, rather than a
mixed group including non-amnestic MCI. Another
cohort followed by us longitudinally over 2 years, and
younger on average by 10 years than patients in the
study reported here, also shows a high percentage of
conversion (49%) within this period (unpublished results).
The present cohort was older, so the period between
aMCI being diagnosed and onset of dementia may well be
accelerated as cognitive reserve declines with increasing
age. All the patients in this study were in an early stage
of disease, so it is not surprising that neither marked
differences in OI ability, nor reductions in brain structural
volume according to diagnosis were found. Clinically, it is
not easy to clearly differentiate aMCI from early AD, and
recent proposals for harmonizing new diagnostic criteria
will attempt to simplify and standardize terminology
in AD, whether prodromal or in the dementia phase
[38]. Simple tests that help determine early changes
are necessary for identifying individuals most at risk,
and in our study, olfaction rather than memory, seemed
to relate better to the size of hippocampus.
Conclusions
The results of this study suggest that competence in
olfactory identification rather than memory is associated
with the volume of several brain structures, particularly
hippocampus in aMCI and AD. This result was found
regardless of whether the B-SIT or SSIT olfactory test
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http://www.biomedcentral.com/1471-2377/14/168was employed, and not only distinguished patients with
aMCI and early AD from healthy control individuals,
but also suggested that patients with greater olfactory
impairment have increased brain atrophy. These results
require confirmation in a larger patient population.
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